CN112654627A - 杂环化合物 - Google Patents

杂环化合物 Download PDF

Info

Publication number
CN112654627A
CN112654627A CN201980058108.7A CN201980058108A CN112654627A CN 112654627 A CN112654627 A CN 112654627A CN 201980058108 A CN201980058108 A CN 201980058108A CN 112654627 A CN112654627 A CN 112654627A
Authority
CN
China
Prior art keywords
compound
ring
group
optionally substituted
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980058108.7A
Other languages
English (en)
Chinese (zh)
Inventor
大达一弘
藤森悠介
牧田直也
古关教孝
林秀树
坂元裕树
峰野胡桃
多贺亮介
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Publication of CN112654627A publication Critical patent/CN112654627A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CN201980058108.7A 2018-09-07 2019-09-06 杂环化合物 Pending CN112654627A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018167488 2018-09-07
JP2018-167488 2018-09-07
PCT/JP2019/035233 WO2020050409A1 (en) 2018-09-07 2019-09-06 Heterocyclic compound

Publications (1)

Publication Number Publication Date
CN112654627A true CN112654627A (zh) 2021-04-13

Family

ID=68063002

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980058108.7A Pending CN112654627A (zh) 2018-09-07 2019-09-06 杂环化合物

Country Status (12)

Country Link
US (2) US11932657B2 (cg-RX-API-DMAC7.html)
EP (1) EP3847176A1 (cg-RX-API-DMAC7.html)
JP (1) JP7448527B2 (cg-RX-API-DMAC7.html)
KR (1) KR102810086B1 (cg-RX-API-DMAC7.html)
CN (1) CN112654627A (cg-RX-API-DMAC7.html)
AU (2) AU2019335968B2 (cg-RX-API-DMAC7.html)
CA (1) CA3109610A1 (cg-RX-API-DMAC7.html)
EA (1) EA202190654A1 (cg-RX-API-DMAC7.html)
IL (1) IL280821B2 (cg-RX-API-DMAC7.html)
SG (1) SG11202101963XA (cg-RX-API-DMAC7.html)
TW (1) TWI854995B (cg-RX-API-DMAC7.html)
WO (1) WO2020050409A1 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115215720A (zh) * 2021-04-19 2022-10-21 中国科学院化学研究所 含薁单元的石墨烯纳米片段分子—薁并玉红省及其合成方法与应用
WO2022228399A1 (zh) * 2021-04-27 2022-11-03 山东轩竹医药科技有限公司 三并环类usp1抑制剂及其用途

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7448527B2 (ja) 2018-09-07 2024-03-12 大塚製薬株式会社 ヘテロ環式化合物
CA3155466A1 (en) 2019-12-09 2021-06-17 Otsuka Pharmaceutical Co., Ltd. Acrylamide compounds
JP2023515128A (ja) 2020-02-26 2023-04-12 ジャガー セラピューティクス ピーティーイーリミテッド Ahrシグナル伝達の調節に有用なピリドピリミジン誘導体
CN114181212B (zh) * 2020-09-15 2023-06-06 山东轩竹医药科技有限公司 哒嗪酮类AhR抑制剂
WO2023033741A1 (en) * 2021-09-02 2023-03-09 Jaguahr Therapeutics Pte Ltd Compounds useful in modulation of ahr signalling
CN118076613A (zh) * 2021-09-02 2024-05-24 捷豹治疗有限公司 可用于调节AhR信号传导的化合物
WO2023033742A1 (en) * 2021-09-02 2023-03-09 Jaguahr Therapeutics Pte Ltd Compounds useful in modulation of ahr signalling
CN119948035A (zh) 2022-10-03 2025-05-06 捷豹治疗有限公司 可用于调节AhR信号传导的化合物
WO2024090138A1 (ja) * 2022-10-29 2024-05-02 松本油脂製薬株式会社 弾性繊維用処理剤及びその利用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20100362A1 (es) 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
EA026134B1 (ru) 2010-12-16 2017-03-31 Ф. Хоффманн-Ля Рош Аг Трициклические ингибиторы pi3k и способы их применения
WO2014138485A1 (en) 2013-03-08 2014-09-12 Irm Llc Ex vivo production of platelets from hematopoietic stem cells and the product thereof
WO2016204256A1 (ja) 2015-06-16 2016-12-22 国立大学法人京都大学 高機能性血小板の製造方法
MX2019012431A (es) 2017-04-21 2020-08-03 Ikena Oncology Inc Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
WO2019167973A1 (en) 2018-03-01 2019-09-06 Kyoto University Cell cycle progression inhibitor
JP7448527B2 (ja) 2018-09-07 2024-03-12 大塚製薬株式会社 ヘテロ環式化合物
CA3155466A1 (en) 2019-12-09 2021-06-17 Otsuka Pharmaceutical Co., Ltd. Acrylamide compounds
JP2022188761A (ja) 2021-06-09 2022-12-21 大塚製薬株式会社 窒素原子含有複素環化合物を用いる血小板産生方法

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115215720A (zh) * 2021-04-19 2022-10-21 中国科学院化学研究所 含薁单元的石墨烯纳米片段分子—薁并玉红省及其合成方法与应用
CN115215720B (zh) * 2021-04-19 2023-08-22 中国科学院化学研究所 含薁单元的石墨烯纳米片段分子—薁并玉红省及其合成方法与应用
WO2022228399A1 (zh) * 2021-04-27 2022-11-03 山东轩竹医药科技有限公司 三并环类usp1抑制剂及其用途
CN117355532A (zh) * 2021-04-27 2024-01-05 山东轩竹医药科技有限公司 三并环类usp1抑制剂及其用途

Also Published As

Publication number Publication date
KR20210056373A (ko) 2021-05-18
KR102810086B1 (ko) 2025-05-21
TWI854995B (zh) 2024-09-11
EA202190654A1 (ru) 2021-05-27
WO2020050409A1 (en) 2020-03-12
AU2024203760A1 (en) 2024-06-20
AU2019335968A1 (en) 2021-05-06
CA3109610A1 (en) 2020-03-12
TW202035423A (zh) 2020-10-01
JP2021536482A (ja) 2021-12-27
SG11202101963XA (en) 2021-03-30
IL280821A (en) 2021-04-29
NZ774547A (en) 2025-10-31
US20240208999A1 (en) 2024-06-27
JP7448527B2 (ja) 2024-03-12
EP3847176A1 (en) 2021-07-14
IL280821B1 (en) 2024-10-01
US20210340157A1 (en) 2021-11-04
US11932657B2 (en) 2024-03-19
IL280821B2 (en) 2025-02-01
AU2019335968B2 (en) 2024-03-07

Similar Documents

Publication Publication Date Title
JP7448527B2 (ja) ヘテロ環式化合物
JP5159305B2 (ja) チエノトリアゾロジアゼピン化合物及びその医薬としての用途
CN107231802B (zh) 杂环衍生物及其用途
CN112424200B (zh) 作为溴区结构域蛋白抑制剂的亚氨基砜类化合物、药物组合物及其医药用途
RU2681849C2 (ru) Гетероциклические производные и их применение
TWI836960B (zh) 作為a2a抑制劑的硫胺甲酸酯衍生物以及用於癌症治療的方法
WO2015057963A1 (en) Fgfr4 inhibitors
JP2010111624A (ja) Ttk阻害作用を有するインダゾール誘導体
WO2019101086A1 (zh) 卤代烯丙基胺类ssao/vap-1抑制剂及其应用
CN102762099A (zh) 作为mTOR和P13K抑制剂的新颖嘧啶化合物
CN111566100B (zh) 嘧啶类化合物、其制备方法及其医药用途
KR20120034607A (ko) 이미다조〔2,1-b〕〔1,3,4〕티아디아졸 유도체
CN120917003A (zh) 酰基磺酰胺kat6a抑制剂
JP2006515596A (ja) Pparデルタ活性化化合物として用いられるインドールフェニルスルホンアミド誘導体
CN110156656A (zh) 五元杂芳环衍生物、其制备方法、药物组合物及应用
WO2021228215A1 (zh) 可用作RORγ调节剂的联芳基类化合物
HK40048052A (zh) 杂环化合物
JP7657800B2 (ja) アクリルアミド化合物
CN115785154A (zh) 杂芳环化合物及其医药用途
JP2022188761A (ja) 窒素原子含有複素環化合物を用いる血小板産生方法
HK40059281A (en) BIARYL COMPOUNDS USEFUL AS RORγMODULATORS
HK40068949A (en) Acrylamide compounds
CN105263926A (zh) 苯并噻吩化合物
HK40044332B (en) Sulfoximine compound as bromodomain protein inhibitor and pharmaceutical composition and medical use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40048052

Country of ref document: HK